Real-world evidence of osimertinib in Chinese patients with EGFR T790M-positive non-small cell lung cancer: a subgroup analysis from ASTRIS study
Qing Zhou(Jiangnan University), Yi‐Long Wu(Guangdong Academy of Medical Sciences), Helong Zhang(Shanghai International Studies University), Caicun Zhou(Tongji University), Jianying Zhou(First Affiliated Hospital Zhejiang University), Gang Wu(Hubei University of Chinese Medicine), Liyan Jiang(Southwest University), Ying Cheng(Jilin Province Tumor Hospital), Yanping Hu(Chinese People's Liberation Army), Cuiying Zhang(Tianjin University of Science and Technology), Yiping Zhang(Zhejiang Cancer Hospital), Yuan Chen(Tongji Hospital), Jie Wang(Chinese Academy of Medical Sciences & Peking Union Medical College), You Lü(Sichuan University), Yong Song(Nanjing General Hospital of Nanjing Military Command), Changli Wang(Tianjin Medical University Cancer Institute and Hospital), Yuankai Shi(Chinese Academy of Medical Sciences & Peking Union Medical College), Jianxing He(First Affiliated Hospital of Guangzhou Medical University), Jinming Yu(Shandong University), Wenlei Zhuo(Army Medical University), Yunpeng Liu(Shenyang Institute of Automation), Shun Lü(Shanghai Jiao Tong University), Gongyan Chen(Harbin Medical University), Yong He(Army Medical University)
Cited by 9
Related Papers
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
|New England Journal of Medicine|2009|8.2k
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
|The Lancet Oncology|2011|4.1k
Pembrolizumab plus Chemotherapy for Squamous Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.7k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k